Vorinostat is a histone deacetylase (HDAC) inhibitor. Histone deacetylase (HDAC) inhibitors are a new class of potential anticancer agents for the treatment of solid and hematological malignancies.
This is a drug that was used in the largest clinical trial for malignant pleural mesothelioma in Europe. The disturbing fact is that, according to a report published last December is that it failed as a second-line-treatment for this deadly tumor in the chest lining. Dr. Rolf A. Stahel of the University Hospital Zurich lamented, "This has been the largest study ever in mesothelioma…Despite this huge effort, the result is negative." Despite the negative results, just by its sheer size, the trial definitely provided an excellent source of information which will be helpful for further trials.
In February 2013, Keiran Smalley, of The Moffitt Cancer Center & Research Institute, United States of America wrote a great article titled “Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression”. In it, the following is written as a summary. The report stated that in summary 3D models were used to show the value of histone deacetylase inhibition in undermining multicellular resistance to chemotherapy. This raised the possibility that resistance of the tumor cells is mediated via epigenetic mechanisms.
Chemo responsiveness can be enhanced directly or indirectly. These direct and indirect strategies could be used together, especially if it enhances Bim expression in tumors with low baseline expression. These studies may provide the basis for the use of these agents in combination in future clinical trials. For the complete article please see the link below.
This is a drug approved by the Food and Drug Administration to treat cutaneous T-cell lymphoma. The standard dose is 400 milligrams per day. It is manufactured by Merck & Company. Further recent results of phase 1 clinical trial indicate that a High-dose of the drug is effective at treating relapsed lymphomas especially the treating of aggressive blood cancer.
Vorinostat has also been know to have some side effects:
Some important things anyone has to remember about the side effects of Vorinostat are:
It is very important that you get guidance from your doctor. This information is for information only.
It is believed that most people will not experience all of the Vorinostat side effects listed. It is believed that Vorinostat has side effects that are often predictable in terms of their onset, duration, and severity. It’s side effects are almost always reversible and do go away after the therapy is complete. There is no direct relationship between the presence of the side effects and the effectiveness of the medication. The side effects may be manageable and there are many options to minimize or prevent them.
Read more in the links below.
More links :